Ceva Animal Health invests in new 7,000 m² vaccine manufacturing facility to expand global production capacity
Ceva animal health (Ceva) unveils its latest investment in European vaccine manufacturing, with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia. This development will establish a 7,000 m2 plant in Monor, Hungary withthe most advanced technologies,where Ceva will produce fermentation-based multicomponent inactivated vaccines for animals.
Ceva Animal Health (Ceva)
For over 20 years, Ceva has been a strong advocate for prevention through vaccination, heavily investing in preventive medicine to significantly improve the health of husbandries but also to fight zoonotic and emerging diseases, contributing to prepare for future pandemics.
Today, 54% of Ceva’s R&D budget is dedicated to vaccine development and the company already provides more than 50 vaccines to fight 19 zoonotic diseases.
With this investment, it will further strengthen its position, producing more than 8 billion doses of vaccines in this new manufacturing plant annually, on top of other animal health products.
“Building a new facility is always a significant milestone in the life of a company. In Hungary, we already benefit from a strong historical expertise with our Ceva Phylaxia campus. With the addition of this new production unit in Monor, we aim to create new synergies to advance preventive medicine. This project reflects our commitment to supporting farmers worldwide by developing tailored solutions to tackle emerging diseases and new variants. It embodies our ambition to build a promising future for our company, employees, and partners, both in Hungary and internationally, while strengthening our research and development capabilities.” says Marc Prikazsky, Chairman and CEO of Ceva Animal Health.
The new plant is scheduled to start operations at the end of 2026.
Other news from the department manufacturing
